KR20020049031A - 생체내 유전자 송달에 의하여 심혈관 질환을 치료하기위한 기술 및 조성물 - Google Patents

생체내 유전자 송달에 의하여 심혈관 질환을 치료하기위한 기술 및 조성물 Download PDF

Info

Publication number
KR20020049031A
KR20020049031A KR1020027005855A KR20027005855A KR20020049031A KR 20020049031 A KR20020049031 A KR 20020049031A KR 1020027005855 A KR1020027005855 A KR 1020027005855A KR 20027005855 A KR20027005855 A KR 20027005855A KR 20020049031 A KR20020049031 A KR 20020049031A
Authority
KR
South Korea
Prior art keywords
vector
growth factor
peptide
protein
angiogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020027005855A
Other languages
English (en)
Korean (ko)
Inventor
해몬드에이치.커크
지오르다노프랭크제이.
딜만볼프강에이치.
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20020049031A publication Critical patent/KR20020049031A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020027005855A 1999-11-05 2000-11-03 생체내 유전자 송달에 의하여 심혈관 질환을 치료하기위한 기술 및 조성물 Ceased KR20020049031A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43515699A 1999-11-05 1999-11-05
US09/435,156 1999-11-05
US60908000A 2000-06-30 2000-06-30
US09/609,080 2000-06-30
PCT/US2000/030345 WO2001034208A1 (en) 1999-11-05 2000-11-03 Techniques and compositions for treating cardiovascular disease by in vivo gene delivery

Publications (1)

Publication Number Publication Date
KR20020049031A true KR20020049031A (ko) 2002-06-24

Family

ID=27030448

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027005855A Ceased KR20020049031A (ko) 1999-11-05 2000-11-03 생체내 유전자 송달에 의하여 심혈관 질환을 치료하기위한 기술 및 조성물

Country Status (10)

Country Link
EP (1) EP1225921A1 (https=)
JP (1) JP2003513942A (https=)
KR (1) KR20020049031A (https=)
CN (1) CN1433325A (https=)
AU (1) AU784392B2 (https=)
CA (1) CA2389524A1 (https=)
EA (1) EA008538B1 (https=)
HK (1) HK1048593A1 (https=)
NZ (1) NZ546670A (https=)
WO (1) WO2001034208A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101006106B1 (ko) * 2009-06-04 2011-01-07 김현태 전·자기장 차단 전열선

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034208A1 (en) * 1999-11-05 2001-05-17 The Regents Of The University Of California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US20030093147A1 (en) * 2001-11-13 2003-05-15 Ogle Matthew F. Medical devices that stimulate growth factor production
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
GB2437893A (en) * 2006-07-25 2007-11-07 Celladon Corp Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
EP2559698B1 (en) * 2007-08-24 2014-11-12 Julius-Maximilians-Universität Würzburg Mutant double cyclized receptor peptides inhibiting beta 1-adrenoceptor antibodies
JP5579164B2 (ja) 2008-04-09 2014-08-27 ビロメッド カンパニー， リミテッド 凍結乾燥ｄｎａ製剤、組成物、及び凍結乾燥ｄｎａ製剤を製造する方法
WO2010078624A1 (en) * 2009-01-07 2010-07-15 Vegenics Limited Materials and methods for the treatment of hypertension
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
CA2864100A1 (en) 2012-02-14 2013-08-22 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
WO2013184782A2 (en) 2012-06-05 2013-12-12 Muffin Incorporated Catheter systems and methods useful for cell therapy
US10639351B2 (en) 2013-10-22 2020-05-05 Helixmith Co., Ltd. Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
US20210393805A1 (en) * 2018-05-16 2021-12-23 University Of Massachusetts Perfusion-based delivery of recombinant aav vectors for expression of secreted proteins
KR20210027493A (ko) 2018-07-19 2021-03-10 주식회사 헬릭스미스 네이키드 dna 유전자 요법을 위한 동결 건조된 약제학적 조성물
JP7717677B2 (ja) * 2019-08-07 2025-08-04 ノースウェスタン ユニバーシティ 心臓内遺伝子送達のための材料及び方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034208A1 (en) * 1999-11-05 2001-05-17 The Regents Of The University Of California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
EA001616B1 (ru) * 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
AU745409B2 (en) * 1997-01-29 2002-03-21 Cornell Research Foundation Inc. Multiple site delivery of adenoviral vector for the induction of angiogenesis
KR20010012313A (ko) * 1997-05-06 2001-02-15 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 혈관형성성 트랜스유전자의 생체내 송달에 의한 심장 질환및 심실 리모델링을 치료하기 위한 방법 및 조성물
JP2002502885A (ja) * 1998-02-11 2002-01-29 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 増強された遺伝子送達のための、核酸および血管作用性薬剤の組合せ
EP1139751A4 (en) * 1998-12-28 2003-03-19 Arch Dev Corp EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101006106B1 (ko) * 2009-06-04 2011-01-07 김현태 전·자기장 차단 전열선

Also Published As

Publication number Publication date
EP1225921A1 (en) 2002-07-31
CA2389524A1 (en) 2001-05-17
NZ546670A (en) 2009-02-28
AU1460401A (en) 2001-06-06
JP2003513942A (ja) 2003-04-15
WO2001034208A1 (en) 2001-05-17
EA008538B1 (ru) 2007-06-29
EA200200533A1 (ru) 2002-12-26
HK1048593A1 (zh) 2003-04-11
AU784392B2 (en) 2006-03-23
CN1433325A (zh) 2003-07-30

Similar Documents

Publication Publication Date Title
US20090082293A1 (en) Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US6583276B1 (en) Angiogenic factors and use thereof in treating cardiovascular disease
US20080254109A1 (en) Localized myocardial injection method for treating ischemic myocardium
KR20020049031A (ko) 생체내 유전자 송달에 의하여 심혈관 질환을 치료하기위한 기술 및 조성물
AU770384B2 (en) Methods of altering cardiac cell phenotype
CA2289600C (en) Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
CN100350979C (zh) 核酸和血管活性剂相组合用于加强的基因投递
WO2002002148A2 (en) Dual recombinant gene therapy compositions and methods of use
US20130096500A1 (en) Nucleic acid based cardiovascular therapeutics
AU2006200170B2 (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
US20160296674A1 (en) Nucleic acid based cardiovascular therapeutics
HK1094944A (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
WO2009039217A1 (en) Medicaments for the treatment of coronary syndromes

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20020506

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20051103

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20061109

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20121004

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20061109

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I